background
acut
exacerb
chronic
bronchiti
aecb
common
condit
substanti
associ
cost
morbid
research
effort
focus
innov
reduc
morbid
associ
aecb
health
care
payer
increasingli
expect
result
evidencebas
econom
evalu
guid
practition
choic
costeffect
intervent
object
provid
framework
base
effect
effici
antimicrobi
therapi
aecb
present
concis
clinic
review
aecb
follow
assess
avail
data
econom
impact
diseas
address
sever
aecbspecif
issu
must
consid
costeffect
analys
aecb
antimicrobi
intervent
method
publish
literatur
clinic
econom
impact
aecb
identifi
use
medlin
premedlln
healthstar
clnahl
current
contentsal
edit
embas
intern
pharmaceut
abstract
databas
potenti
sourc
identifi
search
refer
retriev
articl
review
articl
consensu
statement
articl
written
select
author
result
evalu
costeffect
analys
aecb
antimicrobi
therapi
critic
use
diseasefre
interv
outcom
measur
evalu
sequenc
multipl
therapi
address
impact
current
futur
antibiot
resist
measur
appropri
aecbassoci
cost
direct
indirect
incorpor
approach
econom
analys
aecb
antimicrobi
therapi
help
health
care
organ
make
evidencebas
decis
regard
costeffect
manag
aecb
chronic
bronchiti
defin
presenc
mucusproduc
cough
occur
day
month
month
year
success
year
center
diseas
control
prevent
estim
million
individu
unit
state
adult
popul
suffer
condit
make
seventh
common
chronic
diseas
unit
individu
chronic
bronchiti
typic
experi
sever
exacerb
diseas
year
unpredict
event
caus
usual
easili
identifi
demonstr
signific
detriment
impact
qualiti
life
affect
individu
experi
acut
exacerb
chronic
bronchiti
aecb
seek
treatment
health
care
provid
year
million
visit
aecb
occur
unit
ambulatori
manag
usual
lead
eventu
return
baselin
clinic
function
without
need
visit
medic
diagnost
howev
particularli
sever
episod
unusu
case
outpati
care
unsuccess
hospit
requir
hospit
admiss
unit
state
attribut
aecb
year
epidemiolog
associ
morbid
broad
rang
medic
servic
requir
make
aecb
signific
econom
burden
health
care
sector
societi
whole
annual
direct
medic
cost
associ
diagnosi
treatment
aecb
estim
l
accur
calcul
total
burden
chronic
bronchiti
complic
sinc
financi
project
tend
exclud
nonmed
direct
cost
eg
famili
caregiv
travel
well
indirect
cost
eg
absente
decreas
product
like
consider
cost
adequ
quantifi
aggreg
financi
burden
diseas
substanti
underestim
signific
resourc
direct
toward
develop
intervent
reduc
morbid
associ
chronic
bronchiti
much
current
research
focus
drug
effect
treat
aecb
andor
reduc
occurr
acut
event
increas
awar
among
health
care
payer
rise
drug
cost
requir
new
agent
demonstr
addit
clinic
benefit
gain
justifi
increment
expenditur
incur
expect
among
payer
result
evidencebas
econom
evalu
guid
practition
choic
costeffect
intervent
although
publish
standard
econom
evalu
exist
critic
address
aecbspecif
issu
tabl
perform
interpret
costeffect
analys
intervent
aecb
particularli
antimicrobi
therapi
aecbspecif
issu
includ
advanc
basic
appli
research
well
clinic
aspect
aecb
differenti
chronic
bronchiti
tabl
acut
exacerb
chronic
bronchiti
aecb
specif
issu
influenc
econom
evalu
evalu
multipl
therapi
prescrib
clinic
practic
sequenc
impact
antibiot
resist
current
futur
measur
appropri
aecbassoci
cost
condit
provid
perspect
provid
framework
base
clinic
relev
discuss
regard
best
clinic
practic
aecb
antimicrobi
manag
present
concis
review
pathogenesi
natur
histori
current
treatment
aecb
follow
assess
avail
data
econom
impact
condit
light
avail
data
potenti
impact
diseasespecif
issu
costeffect
aecb
intervent
explor
detail
analyz
clinic
econom
implic
issu
crucial
make
evidencebas
decis
regard
costeffect
antimicrobi
manag
aecb
publish
literatur
clinic
econom
burden
aecb
identifi
first
use
variou
combin
appropri
medic
subject
head
key
word
eg
chronic
bronchiti
treatment
lung
diseas
obstruct
cost
cost
analysi
computer
search
follow
databas
perform
medlin
premedlin
healthstar
cinahl
current
contentsal
edit
embas
intern
pharmaceut
abstract
sever
databas
also
search
articl
written
select
author
field
chronic
bronchiti
potenti
sourc
identifi
examin
refer
cite
retriev
articl
review
articl
consensu
statement
peerreview
public
report
publish
these
abstract
form
consid
cigarett
smoke
import
caus
declin
pulmonari
function
develop
chronic
bronchitiss
mucociliari
system
primari
defens
mechan
inhal
particl
may
alter
cigarett
smoke
therebi
predispos
patient
secondari
infect
secondari
infect
usual
due
varieti
viral
bacteri
usual
respons
episod
aecb
gener
bacteria
account
exacerb
chronic
bronchiti
tabl
ii
averag
patient
chronic
bronchiti
experi
exacerb
per
year
symptom
last
week
per
patient
episod
aecb
usual
increas
symptom
cough
dyspnea
andor
sputum
product
seek
treatment
health
care
provid
offic
visit
provid
must
choos
type
therapi
eg
antimicrobi
bronchodil
andor
system
corticosteroid
therapi
site
administr
inpati
vs
outpati
decid
whether
treat
patient
antimicrobi
agentand
agent
usei
often
difficult
depend
etiolog
episod
howev
rapid
reliabl
method
predict
etiolog
base
patient
histori
physic
examin
routin
laboratori
test
result
physician
must
reli
epidemiolog
data
predict
like
pathogen
tabl
ii
major
patient
requir
hospit
treatment
patient
moder
sever
underli
diseas
howev
like
hospit
often
less
sever
specif
role
corticosteroid
adjunct
therapi
patient
aecb
clear
data
emerg
howev
corticosteroid
therapi
result
moder
improv
clinic
outcom
among
patient
howev
data
adjunct
treatment
aecb
eg
corticosteroid
bronchodil
observ
method
use
collect
data
often
inconsist
adjust
potenti
confound
factor
given
high
cost
associ
aecb
theoret
unproven
potenti
persist
bacteri
infect
deterior
lung
use
effect
antibiot
therapi
studi
antibiot
efficaci
result
stratifi
base
number
symptom
baselin
increas
dyspnea
increas
sputum
product
andor
chang
sputum
color
patient
symptom
deriv
greatest
benefit
antibiot
therapi
wherea
patient
symptom
benefit
therapi
metaanalysi
trial
randomli
assign
patient
aecb
either
antibiot
therapi
control
found
statist
signific
clinic
small
benefit
patient
treat
antibiot
therapi
fail
significantli
improv
symptom
patient
aecb
patient
characterist
predict
treatment
failur
includ
advanc
age
chest
infect
preced
month
signific
impair
baselin
lung
function
poor
perform
statu
comorbid
patient
increas
risk
treatment
failur
newer
potenti
expens
antimicrobi
agent
could
justifi
earli
therapi
sinc
novel
agent
may
costeffect
use
prevent
costli
outcom
sever
stratif
scheme
consequ
propos
manag
patient
afcb
result
sever
recent
studi
includ
decis
analys
use
computer
prospect
support
use
differ
aecb
antimicrobi
agent
base
patient
stratif
patient
certain
risk
factor
eg
moder
sever
chronic
bronchiti
frequent
exacerb
comorbid
condit
use
newer
broadspectrum
antibiot
led
better
clinic
outcom
lower
overal
health
care
expenditur
despit
higher
initi
drug
acquisit
factor
patient
clinic
characterist
may
affect
antibiot
use
patient
aecb
studi
patient
acut
respiratori
tract
infect
eg
acut
bronchiti
without
underli
lung
diseas
shown
patient
often
demand
antibiot
possibl
unawar
antibiot
effect
viral
moreov
patient
often
expect
receiv
antibiot
prescript
offic
visit
especi
improv
antibiot
prior
expect
enhanc
prolifer
directtoconsum
advertis
addit
manag
care
increas
costconsci
medic
care
affect
way
physician
prescrib
antibiot
although
formulari
design
constrain
pharmaceut
cost
limit
use
certain
expens
antibiot
drive
shorten
prevent
outpati
inpati
visit
encourag
use
broadspectrum
antibiot
ensur
patient
infect
adequ
factor
affect
antibiot
choic
includ
presum
efficaci
safeti
durat
therapi
dose
thu
review
clinic
aspect
aecb
suggest
etiolog
specif
aecb
episod
difficult
determin
patient
high
risk
treatment
failur
earli
recurr
aecb
identifi
use
clinic
histori
individu
treatment
decis
patient
aecb
may
prove
costeffect
accur
calcul
total
econom
burden
aecb
necessari
account
diseaserel
expenditur
appropri
time
cours
measur
resourc
use
societ
perspect
entail
collect
direct
medic
cost
valu
servic
medic
resourc
consum
manag
diseas
direct
nonmed
cost
valu
servic
nonmed
resourc
consum
manag
diseas
indirect
cost
valu
lost
product
prematur
death
relat
diseas
societ
perspect
present
signific
challeng
investig
patientlevel
data
varieti
sourc
eg
insur
compani
patient
famili
caregiv
employ
requir
difficulti
data
collect
econom
data
avail
aecb
address
direct
medic
cost
direct
medic
cost
aecb
includ
incur
outpati
care
hospit
emerg
room
visit
drug
cost
publish
studi
evalu
econom
impact
aecb
conclud
direct
medic
expenditur
attribut
chronic
obstruct
pulmonari
diseas
copd
substanti
use
medicar
claim
nation
databas
niederman
estim
annual
cost
aecb
unit
state
billion
use
broader
inclus
criteria
limit
patient
aecb
ie
use
patient
chronic
bronchiti
primari
secondari
diagnosi
wilson
et
estim
cost
chronic
bronchiti
unit
state
billion
per
year
studi
major
expenditur
associ
hospit
physician
visit
updat
find
deriv
averag
cost
hospit
aecb
acut
chronic
bronchiti
addit
sourc
use
data
univers
healthsystem
consortium
uhc
clinic
databas
us
academ
hospit
univers
michigan
health
system
tabl
iii
publish
analys
appreci
differ
detect
databas
averag
cost
per
hospit
aecb
acut
chronic
bronchiti
increas
mean
cost
inflat
adjust
compar
cost
obtain
niederman
et
wilson
et
may
attribut
greater
sever
ill
often
seen
patient
admit
academ
medic
center
although
ambulatori
manag
aecb
norm
publish
data
suggest
outpati
servic
physician
visit
diagnost
test
emerg
servic
contribut
significantli
less
aecb
cost
inpati
stay
niederman
et
estim
averag
cost
per
visit
physician
offic
visit
hospit
outpati
clinic
visit
emerg
depart
visit
sever
studi
shown
outpati
prescript
medic
import
compon
aecb
total
contribut
outpati
prescript
aggreg
aecb
expenditur
invers
relat
sever
ill
signific
econom
impact
diseaserel
hospit
thu
studi
focu
primari
care
practic
less
sever
ill
popul
would
expect
greater
proport
aecb
cost
attribut
outpati
medic
compar
specialtybas
studi
enrol
sever
ill
patient
like
hospit
relationship
diseas
sever
rate
outpati
drug
contribut
illustr
studi
van
barlingen
et
al
report
outpati
drug
cost
vari
invers
sever
aecb
contribut
drug
cost
total
cost
aecb
rang
sever
exacerb
mild
exacerb
critic
role
hospit
decreas
outpati
drug
cost
contribut
seen
studi
destach
et
aecb
patient
cohort
patient
eventu
hospit
outpati
pharmaci
cost
per
aecb
episod
rang
total
treatment
cost
variat
explain
antibiot
use
treat
aecb
exacerb
two
populationbas
demonstr
outpati
prescript
cost
signific
compon
total
aecb
expenditur
hospit
rare
wilson
use
expert
opinion
literatur
review
wholesal
drug
price
estim
total
cost
medic
treatment
chronic
bronchiti
billion
direct
medic
grossman
et
estim
total
cost
antibiot
concomit
medic
use
episod
aecb
account
total
cost
cost
associ
nurs
home
care
paid
unpaid
home
health
care
famili
outofpocket
expenditur
nonmed
expens
eg
travel
day
care
like
contribut
significantli
total
cost
aecb
data
scarc
niederman
et
estim
nurs
home
care
account
total
aecb
treatment
cost
grossman
estim
outofpocket
expens
patient
caregiv
total
aecb
cost
per
episod
indirect
cost
burden
aecb
includ
lost
labor
time
product
patient
caregiv
grossman
et
found
time
lost
work
vari
per
episod
aecb
depend
antibiot
use
indirect
cost
rel
direct
cost
vari
examin
data
anoth
chronic
respiratori
condit
opdto
obtain
rough
estim
proport
indirect
cost
rel
direct
medic
cost
sullivan
et
estim
indirect
cost
copd
billion
almost
two
third
direct
medic
cost
studi
need
clarifi
amount
indirect
expenditur
rel
direct
cost
aecb
summari
econom
impact
aecb
substanti
patient
health
care
system
societi
although
direct
medic
cost
data
analys
perform
date
rather
sophist
work
necessari
better
quantifi
direct
nonmed
indirect
cost
aecb
clinic
research
costeffect
analys
truli
guid
clinic
import
decis
use
patient
employ
resourc
episod
aecb
must
clarifi
given
substanti
clinic
econom
consequ
aecb
develop
clinic
relev
evidencebas
recommend
guid
costeffect
antimicrobi
manag
becom
paramount
determin
econom
effici
antimicrobi
treatment
specif
patient
popul
straightforward
sever
uniqu
diseasespecif
analyt
issu
exist
must
consid
determin
costeffect
antimicrobi
therapi
patient
aecb
tabl
econom
studi
explicitli
discuss
appropri
incorpor
consider
analys
use
diseasefre
interv
dfi
infectionfre
interv
outcom
measur
aecb
treatment
debat
aecb
commonli
use
definit
dfi
length
time
day
end
therapi
begin
next
aecb
episod
current
standard
outcom
use
clinic
trial
aecb
intervent
symptomat
cure
index
exacerb
clinic
improv
primari
outcom
analysi
aecb
therapi
howev
sinc
chronic
bronchiti
associ
multipl
relaps
evalu
focus
exclus
singl
exacerb
may
shortsight
publish
trial
conclud
give
patient
certain
antibiot
may
prolong
time
period
aecb
scientif
rational
behind
dfi
lie
level
bacteri
erad
achiev
antibiot
number
bacteria
colon
lower
airway
decreas
substanti
hypothes
recurr
symptomat
episod
delay
thu
advantag
treatment
significantli
delay
futur
exacerb
independ
cure
rate
index
episod
obviou
dfi
differ
significantli
among
avail
therapi
effect
clinic
outcom
resourc
use
would
substanti
given
recurr
natur
thu
antibiot
could
prove
benefici
base
success
failur
rate
incid
aecb
episod
also
effect
dfi
incorpor
dfi
outcom
current
aecb
decisionanalyt
need
expand
allow
clinic
followup
extend
end
incid
exacerb
cure
fail
death
end
point
base
chronolog
base
month
year
sever
aspect
clinic
cours
must
record
accur
estim
impact
dfi
specif
clinic
predictor
may
affect
probabl
subsequ
aecb
must
captur
store
includ
antibiot
use
incid
exacerb
comorbid
condit
sever
exacerb
thu
comprehens
evalu
aecb
includ
dfi
outcom
measur
better
assist
decisionmak
determin
costeffect
specif
therapi
compar
evalu
assess
singl
episod
aecb
constrain
health
care
expenditur
clinic
practic
guidelin
aecb
treatment
often
recommend
initi
use
less
expens
less
effect
treatment
reserv
effect
expens
regimen
treatment
failur
patient
aecb
may
fail
initi
therapi
experi
relaps
initi
therapi
prescrib
clinic
econom
consequ
antibiot
therapi
depend
subsequ
diagnost
treatment
decis
occur
entir
natur
cours
diseas
given
recur
natur
chronic
bronchiti
evalu
treatment
prescrib
cours
diseas
instead
singl
exacerb
like
yield
accur
costeffect
data
analys
compar
antibiot
directli
firstlin
antibiot
vs
secondlin
antibiot
may
reflect
actual
clinic
practic
sinc
avail
altern
often
use
sequenc
ie
firstlin
antibiot
fail
secondlin
antibia
otic
use
costeffect
firstlin
antibiot
agent
aecb
consequ
depend
entir
differ
bronchiti
cure
rate
treatment
cost
time
use
also
variat
patient
symptomat
respons
result
likelihood
futur
bronchitisrel
health
care
expenditur
econom
analys
aecb
consid
recur
natur
condit
account
sever
treatment
chang
appropri
time
period
one
import
cost
differenti
antimicrobi
agent
pharmaceut
class
potenti
organ
develop
resist
specif
drug
prospect
surveil
program
quantifi
resist
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
bacteria
commonli
implic
aecb
mani
antibiot
doern
et
report
data
pneumonia
isol
medic
center
unit
state
isol
institut
canada
although
resist
rate
vari
wide
overal
isol
suscept
penicillin
wherea
demonstr
intermedi
resist
demonstr
highlevel
resist
also
observ
among
common
gramneg
respiratori
isol
h
influenza
although
vitro
data
indic
signific
level
resist
vivo
impact
antibiot
resist
patient
bronchiti
remain
unclear
studi
clearli
demonstr
patient
infect
resist
strain
wors
outcom
similar
patient
infect
suscept
strain
patient
infect
resist
organ
wors
prognosi
abil
select
effect
antibiot
initi
present
would
critic
deceler
rate
antibiot
resist
particularli
problemat
develop
futur
resist
correl
current
antibiot
report
canadian
bacteri
surveil
network
found
preval
pneumonia
reduc
suscept
fluoroquinolon
increas
use
fluoroquinolon
increas
period
limit
excess
use
antibiot
success
reduc
broadspectrum
agent
frequent
use
empir
patient
aecb
physician
must
recogn
tradeoff
initi
effect
therapi
result
likelihood
futur
resist
howev
method
stop
cycl
remain
elus
evidencebas
econom
analys
consid
societ
perspect
may
help
clarifi
tradeoff
optim
care
individu
patient
today
ensur
effect
therapi
futur
patient
aecb
thu
studi
incorpor
clinic
effect
futur
resist
pattern
econom
impact
determin
optim
treatment
aecb
clearli
need
discuss
financi
impact
aecb
patient
health
care
system
societi
substanti
although
direct
medic
cost
data
diseas
avail
data
quantifi
addit
aecbrel
expenditur
paid
thirdparti
payer
scant
clinic
research
costeffect
analys
truli
guid
clinic
relev
decis
sizabl
invest
clarifi
aecbassoci
resourc
use
warrant
recommend
base
exclus
direct
medic
cost
may
lead
clinician
choos
intervent
benefit
health
plan
actual
lead
increas
cost
patient
famili
employ
specif
substanti
clinic
benefit
may
foregon
use
better
therapi
restrict
base
high
acquisit
price
alon
concomitantli
underestim
potenti
benefit
eg
failur
includ
decreas
absente
intervent
slow
prevent
develop
chronic
bronchiti
decreas
number
aecb
episod
keep
patient
requir
medic
care
servic
play
import
role
clinic
manag
diseas
given
clinic
econom
impact
aecb
emerg
antimicrobi
strain
resist
commonli
avail
drug
import
effect
costeffect
antimicrobi
therapi
never
greater
although
establish
benefit
antimicrobi
therapi
patient
aecb
problemat
use
patient
becom
standard
thu
select
costeffect
initi
therapi
crucial
symptomat
patient
societi
given
widespread
concern
emerg
antibiot
resist
although
costeffect
analys
may
help
determin
optim
initi
therapi
aecbspecif
issu
discuss
articl
must
explicitli
consid
econom
evalu
inform
decis
regard
antimicrobi
therapi
aecb
made
work
support
part
grant
aetna
qualiti
care
research
fundaventi
kansa
citi
missouri
content
project
sole
respons
author
necessarili
repres
offici
view
sponsor
affili
